NEW YORK (GenomeWeb) – Startup CS Genetics has begun the process of introducing what it believes is a novel and superior method for disease detection and assessment via circulating nucleic acids.
Though the company has not shared data publicly that demonstrates this, the firm believes it can develop tests to screen for early-stage cancers, as well as for other applications that would rely on tracking cell-free DNA to particular locations or origins in the body.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.